

Abstract

Motivation - Timely assessment and management of individuals following radiological incidents is a critical capability supporting national security objectives. In a radiological or nuclear event, realistic exposures may incur differential doses to organs and bone marrow. Existing radiation exposure biomarkers, however, do not account for partial body shielding and bone marrow sparing.

Methods - In this study, male and female nonhuman primates (NHPs) were either total body irradiated (TBI) with 5.5 Gy or partial body irradiated (PBI) with 5.5 Gy and 5% bone marrow shielding. Serum, saliva, and urine were collected pre-exposure and up to 60 days following irradiation. Biomarkers listed in previous TBI studies were identified and analyzed in PBI populations. Untargeted metabolomic analysis through liquid chromatography high resolution time-of-flight mass spectrometry (LC-MS) was performed on all three biofluids.

Results & Conclusions - Receiver operating characteristic (ROC) curves show altered urinary response over time. Principal component analysis (PCA) illustrates unique behavior of TBI biomarkers in PBI samples. Results reinforce significance of hematopoietic and gastrointestinal (GI) acute radiation syndromes for medical management.

Urine




Figure 2: A) TBI and B) PBI ROC curves of urine metabolic response throughout 60-day post-irradiation period. ROC curves built using pre-determined TBI biomarkers. C) List of all urine TBI markers sourced from literature and applied to both cohorts. D) Bar graph comparison of 4-Pyridoxate (-) and E) xanthurenate (+) abundances up to one week post-irradiation. All abundances normalized. Results reflect primarily kidney response to radiation type and shielding.

Serum




Figure 3: A) TBI and B) PBI ROC curves of serum metabolic response throughout 60-day post-irradiation period. ROC curves built using pre-determined TBI biomarkers. C) Bar graph comparisons of Acetylcarnitine (+) abundance through 60 days. D) PCA of serum sourced from TBI and E) PBI cohorts separated by 1 week mark. Pre3 included in all PCA analyses. All abundances normalized. Results demonstrate significance of hematopoietic radiation response in biomarker presentation.

Acknowledgements

This work was supported by the Laidlaw Scholars Programme and National Institutes of Health (National Institute of Allergy and Infectious Diseases) grant U01AI148307 (P.I.'s Evagelia C. Laiakis and Frederic Zenhausern). This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN2722015000131 awarded to SRI International. The project described above was also supported by Award Number P30 CA051008 (P.I. Louis Weiner) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.




Figure 1: A) Experimental setup and sample collection times. Three NHPs met euthanasia criteria, four were removed from study. B) Kaplan Meier curve depicts survival rates for all cohorts over 60-day post-irradiation period. Graphics created with BioRender.com.

Conclusions

- Urinary metabolic response is to be expected following both TBI and PBI. Comparative analysis suggests altered kidney physiology due to PBI shielding effects.
- PBI and bone marrow shielded models are reinforced as results indicate strong hematopoietic effect of acute radiation syndrome. Further hematology analysis is required.
- Analysis is ongoing and will consider additional classifications like sex, weight, age, etc. to discern relationships. Results will better elucidate differences in NHP metabolic responses to PBI and TBI.

Saliva




Figure 4: A) Untargeted heatmaps featuring top 100 (+) and (-) measurements for times ≤ 1 week and B) > 1 week. Both heatmaps include pre-irradiation samples. Heatmaps depict changes in ion abundances for each cohort compared to day 3 pre-irradiation. All abundances normalized. Future analysis is necessary to create PBI biomarkers from untargeted LC-MS data.

References

Kosowski, E., Olson, J. D., Gardin, J., Schauf, G. W., Nishita, D., Authier, S., Chang, P., Bremner, D. J., Fornace, A. J., Jr, Cline, J. M., & Laiakis, E. C. (2024). Long-term radiation signal persistence in urine and blood: A two-year analysis in non-human primates exposed to a 4 Gy total-body gamma-radiation dose. *Radiation Research*. Advance online publication. <https://doi.org/10.1667/RADE-23-00261.1>

Laiakis, E. C., Nishita, D., Bujold, K., Jayatilake, M. M., Bakke, J., Gahagen, J., Authier, S., Chang, P., & Fornace, A. J., Jr (2019). Salivary metabolomics of total body irradiated nonhuman primates reveals long-term normal tissue responses to radiation. *International Journal of Radiation Oncology, Biology, Physics*, 103(4), 843–851. <https://doi.org/10.1016/j.ijrobp.2019.07.017>

López, M., & Martin, M. (2011). Medical management of the acute radiation syndrome. *Reports of Practical Oncology and Radiotherapy*, 16(4), 138–146. <https://doi.org/10.1016/j.rpor.2011.05.001>

MacVittie, T. J., Faresse, A. M., & Jackson, W. (2015). The hematopoietic syndrome of the acute radiation syndrome in rhesus macaques: A systematic review of the lethal dose response relationship. *Health Physics*, 109(5), 342–366. <https://doi.org/10.1097/HP.0000000000000352>

MacVittie, T. J., Faresse, A. M., Parker, G. A., Jackson, W., 3rd, Booth, C., Tudor, G. L., Hankey, K. G., & Potten, C. S. (2019). The gastrointestinal subsyndrome of the acute radiation syndrome in rhesus macaques: A systematic review of the lethal dose-response relationship with and without medical management. *Health Physics*, 116(3), 305–338. <https://doi.org/10.1097/HP.0000000000000776>

Pannuk, E. L., Laiakis, E. C., Authier, S., Wong, K., & Fornace, A. J., Jr (2015). Global metabolomic identification of long-term dose-dependent urinary biomarkers in nonhuman primates exposed to ionizing radiation. *Radiation Research*, 184(2), 121–133. <https://doi.org/10.1667/r14091.1>

Pannuk, E. L., Laiakis, E. C., Mak, T. D., Astaria, G., Authier, S., Wong, K., & Fornace, A. J., Jr (2016). A lipidomic and metabolomic serum signature from nonhuman primates exposed to ionizing radiation. *Metabolomics*, 12(5), 80. <https://doi.org/10.1007/s11306-016-1010-0>

Pannuk, E. L., Laiakis, E. C., Garty, G., Bansal, S., Jayatilake, M. M., Tan, Y., Pomatiya, B., Wu, X., Amundson, S. A., Bremner, D. J., & Fornace, A. J., Jr (2018). A metabolomic serum signature from nonhuman primates treated with a radiation countermeasure, gamma-tocotrienol, and exposed to ionizing radiation. *Health Physics*, 115(1), 3–11. <https://doi.org/10.1097/HP.0000000000000776>

Pannuk, E. L., Laiakis, E. C., Garcia, M., Fornace, A. J., Jr, & Singh, V. K. (2018). Nonhuman primates with acute radiation syndrome: Results from a global serum metabolomics study after 7.2 Gy total-body irradiation. *Radiation Research*, 190(6), 576–583. <https://doi.org/10.1667/RR15167.1>

Pannuk, E. L., Laiakis, E. C., Gill, K., Jain, S. K., Mehta, K. Y., Nishita, D., Bujold, K., Bakke, J., Gahagen, J., Authier, S., Chang, P., & Fornace, A. J., Jr (2019). Liquid chromatography–mass spectrometry–based metabolomics of nonhuman primates after 4 Gy total body radiation exposure: Global effects and targeted panels. *Journal of Proteome Research*, 18(5), 2260–2269. <https://doi.org/10.1021/acs.jproteome.9b00101>

Pannuk, E. L., Laiakis, E. C., Garty, G., Bansal, S., Jayatilake, M. M., Tan, Y., Pomatiya, B., Wu, X., Amundson, S. A., Bremner, D. J., & Fornace, A. J., Jr (2024). Impact of partial body shielding from very high dose rates on untargeted metabolomics in biodosimetry. *ACS Omega*, 9(32), 35182–35196. <https://doi.org/10.1021/acsomega.4c05688>

Satyamitra, M. M., DiCarlo, A. L., Hollingsworth, B. A., Winters, T. A., & Talarico, L. P. (2022). Development of biomarkers for radiation biodosimetry and medical countermeasures research: Current status, utility, and regulatory pathways. *Radiation Research*, 197(5), 514–532. <https://doi.org/10.1667/RADE-21-00147.1>